We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$6.75B
AUM Growth
+$53.7M
Cap. Flow
+$466M
Cap. Flow %
6.91%
Top 10 Hldgs %
73.15%
Holding
41
New
5
Increased
16
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$61.6M
2
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$42.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$40.4M
4
APLS
Apellis Pharmaceuticals
APLS
+$28M
5
KRYS icon
Krystal Biotech
KRYS
+$26.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$13.3M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$5.45M

Sector Composition

Rank Sector Weight
1 Healthcare 99.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLUE icon
26
Monte Rosa Therapeutics
GLUE
$1.34B
$33.7M 0.5%
4,325,000
– –
MRSN
27
DELISTED
Mersana Therapeutics
MRSN
$31M 0.46%
302,000
– –
RARE icon
28
Ultragenyx Pharmaceutical
RARE
$2.55B
$30.1M 0.45%
750,000
– –
MRNS
29
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$21.7M 0.32%
3,150,000
– –
WHWK
30
Whitehawk Therapeutics
WHWK
$235M
$20.6M 0.31%
2,849,402
– –
DSGN icon
31
Design Therapeutics
DSGN
$876M
$20.2M 0.3%
3,500,000
+1,227,778
+54% +$9.18M
VRCA icon
32
Verrica Pharmaceuticals
VRCA
$87.3M
$17.2M 0.26%
+265,000
New +$16M
PMVP icon
33
PMV Pharmaceuticals
PMVP
$63.5M
$14.6M 0.22%
3,060,000
– –
AMLX icon
34
Amylyx Pharmaceuticals
AMLX
$2.54B
$13.9M 0.21%
473,100
-156,900
-25% -$5.45M
FENC icon
35
Fennec Pharmaceuticals
FENC
$402M
$9.98M 0.15%
1,200,000
– –
MCRB icon
36
Seres Therapeutics
MCRB
$48.4M
$7.34M 0.11%
+64,750
New +$7M
TNGX icon
37
Tango Therapeutics
TNGX
$4.41B
$6.48M 0.1%
1,640,000
– –
IOBT
38
DELISTED
IO Biotech
IOBT
$3.84M 0.06%
2,055,883
– –
SRPT icon
39
CALL
Sarepta Therapeutics
SRPT
$1.77B
$3.67M 0.05%
+250,000
New +$32.4M
ISEE
40
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.84M 0.03%
+875,000
New +$19.2M
XBI icon
41
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$180K ﹤0.01%
+1,500,000
New +$124M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Avoro Capital Advisors held 41 positions worth $6.75B, up 0.8% from $6.69B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors deployed $466M of net new capital in Q1 2023, opening 5 new positions and adding to 16 existing holdings. Its largest new stake was Verrica Pharmaceuticals: 265,000 shares worth $17.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $13.3M trimmed.

  • Avoro Capital Advisors's largest Q1 2023 buy was Verrica Pharmaceuticals: 265,000 shares worth $17.2M.
  • Avoro Capital Advisors added most to Sarepta Therapeutics in Q1 2023, an estimated $61.6M increase.
  • Avoro Capital Advisors's biggest Q1 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $13.3M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $6.75B portfolio in Q1 2023.
  • Avoro Capital Advisors opened 5 new positions and closed 0 in Q1 2023.
  • Avoro Capital Advisors's portfolio value rose 0.8% quarter-over-quarter to $6.75B.

Based on Avoro Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.